Late Breaking Clinical Trials 3 OCT, IVUS and Pathology

[LB3-5] Effect of Alirocumab on Coronary Atheroma Volume in Japanese Patients with Acute Coronary Syndrome: The ODYSSEY J-IVUS Trial

^○Ako Junya¹, Hibi Kiyoshi², Tsujita Kenichi³, Hiro Takafumi⁴, Morino Yoshihiro⁵, Kozuma Ken⁶, Shinke Toshiro⁷, Otake Hiromasa⁸, Uno Kiyoko⁹, Louie Michael J¹⁰, Takagi Yoshiharu¹¹, Miyauchi Katsumi¹² (1.Department of Cardiovascular Medicine, Kitasato University Hospital, Sagamihara-City, Kanagawa, Japan, 2.Division of Cardiology, Yokohama City University Medical Center, Yokohama-City, Kanagawa, Japan, 3.Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto-City, Kumamoto, Japan, 4.Division of Cardiology, Department of Medicine, Nihon University School of Medicine, Itabashi-ku, Tokyo, Japan, 5.Division of Cardiology, Department of Internal Medicine, Iwate Medical University, Morioka-City, Iwate, Japan, 6.Division of Cardiology, Teikyo University Hospital, Itabashi-ku, Tokyo, Japan, 7.Division of Cardiovascular Medicine, Department of Internal Medicine, Showa University School of Medicine, Shinagawa-ku, Tokyo, Japan, 8.Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe-City, Hyogo, Japan, 9.Cardiovascular Medical, Sanofi, Shinjuku-ku, Tokyo, Japan, 10.Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA, 11.Clinical Sciences and Operations, Sanofi, Shinjuku-ku, Tokyo, Japan, 12.Division of Cardiovascular Medicine, Department of Internal Medicine, Juntendo University Hospital, Bunkyo-ku, Tokyo, Japan)

同通あり